PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11585438-0	2001	Piperazine-based CCR5 antagonists as HIV-1 inhibitors.	Piperazine	0-10	C-C motif chemokine receptor 5	Homo sapiens	17-21	
14521412-0	2003	Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.	Piperazine	95-105	C-C motif chemokine receptor 5	Homo sapiens	50-54	
14521412-1	2003	Predictive pharmacophore models were developed for a large series of piperidine- and piperazine-based CCR5 antagonists as anti-HIV-1 agents reported by Schering-Plough Research Institute in recent years.	Piperazine	85-95	C-C motif chemokine receptor 5	Homo sapiens	102-106	
11585438-4	2001	Further optimization for pharmacokinetic properties afforded Sch-350634 (1), a prototypical piperazine-based CCR5 antagonist, which is a potent inhibitor of HIV-1 entry and replication in PBMCs.	Piperazine	92-102	C-C motif chemokine receptor 5	Homo sapiens	109-113	
24731275-0	2014	Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.	Piperazine	43-53	C-C motif chemokine receptor 5	Homo sapiens	79-83	
11514156-0	2001	Piperazine-based CCR5 antagonists as HIV-1 inhibitors.	Piperazine	0-10	C-C motif chemokine receptor 5	Homo sapiens	17-21	
23308267-0	2013	Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.	Piperazine	53-63	C-C motif chemokine receptor 5	Homo sapiens	79-83	
20347189-1	2010	By employing pharmacophore-based design and the privileged fragments reassembly, a series of piperidine-/tropane-/piperazine-bridged CCR5 antagonists were designed and synthesized via an efficient convergent synthesis strategy, with focus on the optimal choice of the basic center carrier structure.	Piperazine	114-124	C-C motif chemokine receptor 5	Homo sapiens	133-137	
15203141-0	2004	Facile synthesis of 4-substituted-4-aminopiperidine derivatives, the key building block of piperazine-based CCR5 antagonists.	Piperazine	91-101	C-C motif chemokine receptor 5	Homo sapiens	108-112	
18019544-4	2007	Thus, a SAR study of our synthesized piperazinopiperidine-based CCR5 antagonists was conducted with respect to the structure and configuration of the substituent on the piperazine ring.	Piperazine	169-179	C-C motif chemokine receptor 5	Homo sapiens	64-68	
18019544-6	2007	By using the forward-synthesis approach, the best compound in the chiral piperazine-based CCR5 antagonist series, Sch-D (Vicriviroc), was conveniently synthesized in an excellent yield.	Piperazine	73-83	C-C motif chemokine receptor 5	Homo sapiens	90-94	
15115380-0	2004	Piperazine-based CCR5 antagonists as HIV-1 inhibitors.	Piperazine	0-10	C-C motif chemokine receptor 5	Homo sapiens	17-21